RxDoctor Payments Data

Amanda Russo

Family · Humble, TXNPI 1952881229

Payments from drug & device makers

$3,499in general payments, 2019–2025

Across 97 payments — averaging $36.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Merck$442
  • Cvrx, Inc.$184
  • Bridgebio Pharma, Inc.$179
  • Inspire Medical Systems, Inc.$145
  • Amgen$131
  • plus $860 from 16 others

What the payments were for

  • Travel & lodging$1,20634%
  • Food & beverage$2,29466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,499 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan43$48,148
EliquisApixaban39$47,029
Repatha SureclickEvolocumab52$40,150
XareltoRivaroxaban26$31,269
Repatha SyringeEvolocumab15$16,608
BrilintaTicagrelor12$11,398
VascepaIcosapent Ethyl12$4,182
Ranolazine ErRanolazine18$2,849
Ezetimibe48$1,438
Metoprolol Succinate78$1,179
Rosuvastatin Calcium70$977
Atorvastatin Calcium86$780
ClopidogrelClopidogrel Bisulfate64$763
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide12$702
Nifedipine ErNifedipine33$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$48,14843 claims
PfizerEliquis$18$47,02939 claims
Johnson & JohnsonXarelto$113$31,26926 claims
AstraZenecaBrilinta$67$11,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →